NKG7 Is Required for Optimal Antitumor T-cell Immunity.

Area of Science:

• Immunology
• Cancer Biology
• Molecular Biology

Background:

• CD8+ T cells are vital for antitumor immunity.
• Immune checkpoint blockade (ICB) shows promise in cancer treatment.
• NKG7's role in antitumor immunity is largely unknown despite correlative associations with patient outcomes.

Purpose of the Study:

• To investigate NKG7's function in neoantigen-mediated tumor rejection and ICB immunotherapy.
• To elucidate the molecular mechanisms underlying NKG7's role in T cell responses within the tumor microenvironment.

Main Methods:

• Single-cell RNA sequencing (scRNA-seq) of human tumor datasets.
• Utilized NKG7-deficient and NKG7-reporter mice.
• Employed mouse tumor models to assess tumor growth and immunotherapy response.

Main Results:

• NKG7 expression correlates with cytotoxicity and is found in CD8+ T cells and NK cells.
• NKG7 is essential for intratumoral T cell accumulation and activation.
• NKG7 deficiency accelerates tumor growth and significantly reduces ICB efficacy in mice.

Conclusions:

• NKG7 plays a critical role in T cell-mediated antitumor immunity.
• NKG7 is required for effective tumor rejection and response to immune checkpoint blockade.
• Targeting NKG7 may enhance cancer immunotherapy strategies.